

Edgar Filing: EXEGENICS INC - Form 8-K

EXEGENICS INC  
Form 8-K  
December 03, 2002

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 25, 2002  
-----

EXEGENICS INC.

(Exact name of registrant as specified in its charter)

Delaware	333-26078	75-2402409
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2110 Research Row  
Dallas, Texas 75235

(Address of principal executive  
offices including zip code)

(214) 358-2000

(Registrant's telephone number,  
including area code)

N.A.

-----

(Former name or former address, if changed since last report)

Item 5. Other Events.

On November 25, 2002, we announced that we and Innovative Drug Delivery Systems, Inc. ("IDDS") entered into a termination agreement terminating the merger agreement between the two companies that was entered into on September 19, 2002. In connection with the termination, we purchased a \$500,000 convertible note from IDDS at face amount and paid IDDS \$500,000 to defray, in part, expenses incurred by IDDS that were associated with this transaction.

In addition, on December 3, 2002, we commenced mailing a letter to our stockholders regarding the termination of the merger agreement.

A copy of the termination agreement, attached hereto as Exhibit 2.1, a copy of the joint press release issued on November 25, 2002 announcing the execution of the termination agreement, attached hereto as Exhibit 99.1, and a copy of the letter to our stockholders discussing the termination of the merger agreement, attached hereto as Exhibit 99.2, are incorporated herein by reference. The foregoing description is qualified in its entirety by reference to the full text

Edgar Filing: EXEGENICS INC - Form 8-K

of such exhibits.

Item 7. Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.	Description
2.1	Termination Agreement, dated November 25, 2002, by and among us, IDDS, IDDS Merger Corp. and the stockholders' representatives listed therein.
99.1	Joint Press Release issued by us and IDDS, dated November 25, 2002.
99.2	Letter to Stockholders, dated December 3, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXEGENICS INC.  
(Registrant)

Dated: December 3, 2002  
-----

By: /s/ Ronald L. Goode, Ph.D.  
-----

Ronald L. Goode, Ph.D.  
President and Chief Executive Officer

EXHIBIT INDEX

EXHIBIT NUMBER	DESCRIPTION
-----	-----
2.1	Termination Agreement, dated November 25, 2002, by and among us, IDDS, IDDS Merger Corp. and the stockholders' representatives listed therein.
99.1	Joint Press Release issued by us and IDDS, dated November 25, 2002.
99.2	Letter to Stockholders, dated December 3, 2002.

